• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Insulin-and-Glucagon Artificial Pancreas Versus Insulin-Alone Artificial Pancreas: A Short Review.胰岛素与胰高血糖素人工胰腺对比单纯胰岛素人工胰腺:简要综述
Diabetes Spectr. 2019 Aug;32(3):215-221. doi: 10.2337/ds18-0097.
2
Overnight Glucose Control with Dual- and Single-Hormone Artificial Pancreas in Type 1 Diabetes with Hypoglycemia Unawareness: A Randomized Controlled Trial.夜间低血糖感知障碍的 1 型糖尿病患者应用双重和单激素人工胰腺控制血糖:一项随机对照试验。
Diabetes Technol Ther. 2018 Mar;20(3):189-196. doi: 10.1089/dia.2017.0353. Epub 2018 Feb 2.
3
Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.双激素人工胰腺、单激素人工胰腺与常规胰岛素泵治疗对 1 型糖尿病患者血糖控制的比较:一项开放标签随机对照交叉试验。
Lancet Diabetes Endocrinol. 2015 Jan;3(1):17-26. doi: 10.1016/S2213-8587(14)70226-8. Epub 2014 Nov 27.
4
Outpatient overnight glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial.双激素人工胰腺、单激素人工胰腺或传统胰岛素泵治疗在儿童和青少年 1 型糖尿病患者中的门诊过夜血糖控制:一项开放标签、随机对照试验。
Lancet Diabetes Endocrinol. 2015 Aug;3(8):595-604. doi: 10.1016/S2213-8587(15)00141-2. Epub 2015 Jun 8.
5
Single- and Dual-Hormone Artificial Pancreas for Overnight Glucose Control in Type 1 Diabetes.用于1型糖尿病患者夜间血糖控制的单激素和双激素人工胰腺
J Clin Endocrinol Metab. 2016 Jan;101(1):214-23. doi: 10.1210/jc.2015-3003. Epub 2015 Nov 2.
6
Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials.人工胰腺系统对 1 型糖尿病患者血糖控制的影响:一项门诊随机对照试验的系统评价和荟萃分析。
Lancet Diabetes Endocrinol. 2017 Jul;5(7):501-512. doi: 10.1016/S2213-8587(17)30167-5. Epub 2017 May 19.
7
Design of a dual-hormone model predictive control for artificial pancreas with exercise model.具有运动模型的人工胰腺双激素模型预测控制设计
Annu Int Conf IEEE Eng Med Biol Soc. 2016 Aug;2016:2270-2273. doi: 10.1109/EMBC.2016.7591182.
8
Efficacy of single-hormone and dual-hormone artificial pancreas during continuous and interval exercise in adult patients with type 1 diabetes: randomised controlled crossover trial.单激素和双激素人工胰腺对1型糖尿病成年患者持续运动和间歇运动的疗效:随机对照交叉试验
Diabetologia. 2016 Dec;59(12):2561-2571. doi: 10.1007/s00125-016-4107-0. Epub 2016 Oct 4.
9
Glucagon in artificial pancreas systems: Potential benefits and safety profile of future chronic use.人工胰腺系统中的胰高血糖素:未来长期使用的潜在益处和安全性概况。
Diabetes Obes Metab. 2017 Jan;19(1):13-23. doi: 10.1111/dom.12789. Epub 2016 Nov 9.
10
Randomized trial of a dual-hormone artificial pancreas with dosing adjustment during exercise compared with no adjustment and sensor-augmented pump therapy.与不进行剂量调整及动态血糖监测胰岛素泵治疗相比,运动期间进行剂量调整的双激素人工胰腺随机试验。
Diabetes Obes Metab. 2016 Nov;18(11):1110-1119. doi: 10.1111/dom.12707. Epub 2016 Aug 15.

引用本文的文献

1
Analysis of Glucose Responsive Glucagon Therapeutics using Computational Models of the Glucoregulatory System.基于血糖调节系统计算模型分析葡萄糖反应性胰高血糖素治疗。
Adv Healthc Mater. 2024 Nov;13(29):e2401410. doi: 10.1002/adhm.202401410. Epub 2024 Aug 29.
2
DEMIGOD: A Low-Cost Microcontroller-Based Closed-Loop System Integrating Nanoengineered Sweat-Based Glucose Monitoring and Controlled Transdermal Nanoemulsion Release of Hypoglycemic Treatment with a Software Application for Noninvasive Personalized Diabetes Care.半人半神:一种基于低成本微控制器的闭环系统,集成了纳米工程化的基于汗液的葡萄糖监测以及用于低血糖治疗的可控透皮纳米乳剂释放,并配有用于无创个性化糖尿病护理的软件应用程序。
Micromachines (Basel). 2024 Jul 6;15(7):887. doi: 10.3390/mi15070887.
3
Vasodilatory effects of glucagon: A possible new approach to enhanced subcutaneous insulin absorption in artificial pancreas devices.胰高血糖素的血管舒张作用:人工胰腺装置中增强皮下胰岛素吸收的一种可能新方法。
Front Bioeng Biotechnol. 2022 Sep 21;10:986858. doi: 10.3389/fbioe.2022.986858. eCollection 2022.
4
Insulin: evolution of insulin formulations and their application in clinical practice over 100 years.胰岛素:100 多年来胰岛素制剂的发展及其在临床实践中的应用。
Acta Diabetol. 2022 Sep;59(9):1129-1144. doi: 10.1007/s00592-022-01938-4. Epub 2022 Jul 19.
5
Dual-hormone artificial pancreas for management of type 1 diabetes: Recent progress and future directions.双激素人工胰腺治疗 1 型糖尿病:最新进展与未来方向。
Artif Organs. 2021 Sep;45(9):968-986. doi: 10.1111/aor.14023. Epub 2021 Jul 15.
6
Pharmacokinetics of Intraperitoneally Delivered Glucagon in Pigs: A Hypothesis of First Pass Metabolism.腹腔内给予胰高血糖素在猪体内的药代动力学:首过代谢假说。
Eur J Drug Metab Pharmacokinet. 2021 Jul;46(4):505-511. doi: 10.1007/s13318-021-00692-2. Epub 2021 Jun 7.
7
Proglucagon-Derived Peptides as Therapeutics.胰高血糖素原衍生肽类作为治疗药物。
Front Endocrinol (Lausanne). 2021 May 18;12:689678. doi: 10.3389/fendo.2021.689678. eCollection 2021.
8
Felix dies natalis, insulin… ceterum autem censeo "beta is better".费利克斯生日那天,注射了胰岛素……但我认为“β更好”。
Acta Diabetol. 2021 Oct;58(10):1287-1306. doi: 10.1007/s00592-021-01737-3. Epub 2021 May 23.
9
'Smart' insulin-delivery technologies and intrinsic glucose-responsive insulin analogues.智能胰岛素输送技术和内源性葡萄糖响应胰岛素类似物。
Diabetologia. 2021 May;64(5):1016-1029. doi: 10.1007/s00125-021-05422-6. Epub 2021 Mar 12.
10
Engineering biopharmaceutical formulations to improve diabetes management.工程生物制药配方以改善糖尿病管理。
Sci Transl Med. 2021 Jan 27;13(578). doi: 10.1126/scitranslmed.abd6726.

本文引用的文献

1
Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus.低剂量的地特胰岛素可使 1 型糖尿病患者的低血糖和血糖正常时的血糖水平持续升高。
Diabetes Obes Metab. 2019 Mar;21(3):601-610. doi: 10.1111/dom.13562. Epub 2018 Nov 28.
2
Physico-chemical properties of co-formulated fast-acting insulin with pramlintide.与普兰林肽联合使用的速效胰岛素的理化性质。
Int J Pharm. 2018 Aug 25;547(1-2):621-629. doi: 10.1016/j.ijpharm.2018.06.039. Epub 2018 Jun 19.
3
Randomized Outpatient Trial of Single- and Dual-Hormone Closed-Loop Systems That Adapt to Exercise Using Wearable Sensors.随机门诊试验:使用可穿戴传感器适应运动的单激素和双激素闭环系统。
Diabetes Care. 2018 Jul;41(7):1471-1477. doi: 10.2337/dc18-0228. Epub 2018 May 11.
4
Stable Liquid Glucagon: Beyond Emergency Hypoglycemia Rescue.稳定液态胰高血糖素:超越紧急低血糖救治
J Diabetes Sci Technol. 2018 Jul;12(4):847-853. doi: 10.1177/1932296818757795. Epub 2018 Feb 8.
5
Overnight Glucose Control with Dual- and Single-Hormone Artificial Pancreas in Type 1 Diabetes with Hypoglycemia Unawareness: A Randomized Controlled Trial.夜间低血糖感知障碍的 1 型糖尿病患者应用双重和单激素人工胰腺控制血糖:一项随机对照试验。
Diabetes Technol Ther. 2018 Mar;20(3):189-196. doi: 10.1089/dia.2017.0353. Epub 2018 Feb 2.
6
Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog.达格列净的药代动力学和药效学特征,一种新型可溶性和稳定的胰高血糖素类似物。
Diabetes Care. 2018 Mar;41(3):531-537. doi: 10.2337/dc17-1402. Epub 2017 Dec 22.
7
Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials.人工胰腺系统对 1 型糖尿病患者血糖控制的影响:一项门诊随机对照试验的系统评价和荟萃分析。
Lancet Diabetes Endocrinol. 2017 Jul;5(7):501-512. doi: 10.1016/S2213-8587(17)30167-5. Epub 2017 May 19.
8
Closing the Loop in Adults, Children and Adolescents With Suboptimally Controlled Type 1 Diabetes Under Free Living Conditions: A Psychosocial Substudy.在自由生活条件下对成人、儿童和青少年1型糖尿病控制欠佳者进行闭环治疗:一项社会心理子研究
J Diabetes Sci Technol. 2017 Nov;11(6):1080-1088. doi: 10.1177/1932296817702656. Epub 2017 Apr 3.
9
Expectations and Attitudes of Individuals With Type 1 Diabetes After Using a Hybrid Closed Loop System.1型糖尿病患者使用混合闭环系统后的期望和态度
Diabetes Educ. 2017 Apr;43(2):223-232. doi: 10.1177/0145721717697244.
10
Outpatient 60-hour day-and-night glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or sensor-augmented pump therapy in adults with type 1 diabetes: An open-label, randomised, crossover, controlled trial.1型糖尿病成人患者采用双激素人工胰腺、单激素人工胰腺或传感器增强泵疗法进行门诊60小时昼夜血糖控制:一项开放标签、随机、交叉、对照试验。
Diabetes Obes Metab. 2017 May;19(5):713-720. doi: 10.1111/dom.12880. Epub 2017 Mar 8.

胰岛素与胰高血糖素人工胰腺对比单纯胰岛素人工胰腺:简要综述

Insulin-and-Glucagon Artificial Pancreas Versus Insulin-Alone Artificial Pancreas: A Short Review.

作者信息

Haidar Ahmad

机构信息

Department of Biomedical Engineering, McGill University, Montreal, Quebec, Canada.

Division of Endocrinology and Metabolism, Faculty of Medicine, McGill University, Montreal, Quebec, Canada.

出版信息

Diabetes Spectr. 2019 Aug;32(3):215-221. doi: 10.2337/ds18-0097.

DOI:10.2337/ds18-0097
PMID:31462876
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6695257/
Abstract

The advantage of the insulin-and-glucagon artificial pancreas is based on the rapid effect of subcutaneous glucagon delivery in preventing hypoglycemia compared to suspension of insulin delivery. In short-term studies, the dual-hormone artificial pancreas reduced daytime hypoglycemia, especially during exercise, compared to the insulin-alone artificial pancreas, but the insulin-alone system seemed sufficient in eliminating nocturnal hypoglycemia. The comparative benefits of the single- and dual-hormone systems for improving A1C and preventing severe hypoglycemia remain unknown.

摘要

与暂停胰岛素输注相比,胰岛素-胰高血糖素人工胰腺的优势在于皮下注射胰高血糖素在预防低血糖方面起效迅速。在短期研究中,与单激素胰岛素人工胰腺相比,双激素人工胰腺减少了白天的低血糖情况,尤其是在运动期间,但单激素胰岛素系统似乎足以消除夜间低血糖。单激素和双激素系统在改善糖化血红蛋白(A1C)和预防严重低血糖方面的相对益处仍不明确。